drugset / Trial / NCT06904599
Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment
Phase 2
Recruiting
20 enrolled
Hospital Universitario Dr. Jose E. Gonzalez
Dr. Andrés Gómez de León · collabDr. David Gómez Almaguer · collabDr. José Carlos Jaime Perez · collabDra. Consuelo Mancias Guerra · collabDra. Michelle Morcos Sandino · collabDra. Olga Graciela Catú Rodríguez · collabDra. Perla Colunga Pedraza · collabMarisa Romero Martínez · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Graft-versus-host disease is a complication of allogeneic hematopoietic cell transplantation with high morbidity and mortality. The standard treatment is corticosteroids, and based on the response within 3 to 7 days, a second-line therapy is added, which is expensive and not easily accessible. The administration of human chorionic gonadotropin has shown therapeutic effectiveness in 50% of patients in reported clinical cases.
Timeline
- Start
- 2025-02-01
- Primary completion
- 2026-01-31
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | human chorionic gonadotropin | Protein / enzyme biologic | 2500 iu | Intramuscular |
| Comparator | Dexamethasone | Small molecule | 0.15 mg/kg | Intravenous |
| Comparator | Prednisone | Other / unclassified | 1 mg/kg | Oral |